Loading stock data…
EKSO
$11.79-0.22 (-1.83%)
Market ClosedLast close May 1
Ekso Bionics Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ekso Bionics Holdings, Inc. in the Healthcare sector is trading at $11.79. The stock is currently near its 52-week high of $13.50, remaining 73.6% above its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why EKSO maintains its current momentum and trend strength. The Whystock Score of 20/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.79
Potential Upside
5%
Whystock Fair Value$12.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$40.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.78
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-122.80%
Volume
Today's trading volume
47,622
Recent News
Jim Cramer on Applied Digital: A $7.5 Billion Contract Isn’t Enough Without Profits
On the Lightning Round of Mad Money on April 29, 2026, a caller named Bob from Florida told Jim Cramer he was “knee-deep in Applied Digital right now, and they just signed that big $7.5 billion contract.” Cramer’s response cut against the contract-driven enthusiasm: “The problem there is that you’ve got a stock that is ... Jim Cramer on Applied Digital: A $7.5 Billion Contract Isn’t Enough Without Profits
Applied Digital Reshapes AI Cloud And Debt Profile With ChronoScale Move
Applied Digital (NasdaqGS:APLD) is moving to spin off and merge its AI cloud business with EKSO Bionics Holdings to form a new company called ChronoScale. The company has also begun a US$2.15b debt-funded expansion with Polaris Forge 2, reshaping its capital structure. These steps shift how NasdaqGS:APLD is positioned between digital infrastructure, AI cloud services, and balance sheet risk. Applied Digital operates in digital infrastructure tied to AI and high performance computing, a...
Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of +4.73% and +0.13%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
How The Ekso Bionics Holdings Narrative Is Shifting After Q3 And A Higher Price Target
Why Ekso Bionics’ Price Target Just Moved Ekso Bionics Holdings just saw its price target reset to US$6, a level that bullish analysts link to the Q3 update and a view that the company is executing more in line with its current plan. Supporters highlight the Q3 sales recovery and the ongoing business review as reasons to keep the fair value anchor unchanged while expressing more confidence in how the story could unfold, whereas more cautious voices stress that one quarter and an open ended...